
Regeneron Pharmaceuticals company profile
$959.12+0.71%Close 17 Nov 2026 · Market value $102.6B
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Marketed products include EYLEA HD, Libtayo, Praluent, Kevzara, Dupixent (through collaboration), and Lynozyfic, among others. The company uses proprietary platforms, including Trap technology and VelociSuite, to discover and produce fully human antibodies, bispecific antibodies, and gene and RNA-based therapies. It operates across the United States and, through collaborators and licensees such as Sanofi and Bayer, in markets outside the United States.
A summary of the business section of the company's latest annual report, filed 4 Feb 2026.
Company facts
| Ticker | REGN · Nasdaq |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 872589 |
|---|
| Latest annual report | 10-K, filed 4 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Leonard S. Schleifer, M.D., Ph.D. | Bd. Co-Chair, President & CEO · Director | 1.7M · 95% | Shares withheld for tax, 31 Dec 2025 |
|---|
| Andrew J. Murphy, Ph.D. | Co-Chief Scientific Officer | 246K | Gift, 3 Nov 2026 |
|---|
| Joseph J. LaRosa | EVP General Counsel and Secret | 183K | Option exercise, 2 Nov 2026 |
|---|
| Daniel P. Van Plew | EVP & General Mgr, Industrial | 106K | Shares withheld for tax, 9 Dec 2025 |
|---|
| Christopher Fenimore | EVP Finance CFO | 93.9K | Option exercise, 2 Nov 2026 |
|---|
| George L. Sing | Director | 69.2K | Option exercise, 2 Nov 2026 |
|---|
| George D. Yancopoulos, M.D., Ph.D. | Bd. Co-Chair, President & CSO · Director | 42.8K · 2.4% | Option exercise, 31 Dec 2025 |
|---|
| Christine A. Poon | Director | 41.2K | Option exercise, 2 Nov 2026 |
|---|
| Huda Y. Zoghbi, M.D. | Director | 30.7K | Option exercise, 3 Nov 2026 |
|---|
| Arthur F. Ryan | Director | 26.6K | Sale under a 10b5-1 plan, 2 Jul 2026 |
|---|
| Michael S. Brown, M.D. | Director | 19.1K | Option exercise, 30 Oct 2026 |
|---|
| Bonnie L. Bassler, Ph.D. | Director | 17.9K | Sale under a 10b5-1 plan, 7 Jan 2026 |
|---|
| Joseph L. Goldstein, M.D. | Director | 13.0K | Grant or award, 2 Jan 2026 |
|---|
| N. Anthony Coles, M.D. | Director | 10.7K | Grant or award, 2 Jan 2026 |
|---|
| Craig B. Thompson, M.D. | Director | 8.8K | Grant or award, 2 Jan 2026 |
|---|
| Kathryn Guarini, Ph.D. | Director | 6.6K | Option exercise, 30 Oct 2026 |
|---|
| David P. Schenkein, M.D. | Director | 6.6K | Grant or award, 2 Jan 2026 |
|---|
| Pitofsky Jason | SVP Controller | — | Option exercise, 4 Nov 2026 |
|---|
| McCourt Marion | EVP Commercial | — | Sale under a 10b5-1 plan, 30 Oct 2026 |
|---|
| STAHL NEIL | EVP Research and Development | — | Shares withheld for tax, 16 Dec 2024 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
REGN in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.